10月31日 - ** 制药商艾伯维ABBV.N股价早盘下跌3.5%，报220美元
** ABBV的美容产品组合（包括抗皱治疗药物肉毒杆菌）的销售额比去年下降了3.7%。
** BMO Capital Markets分析师埃文-塞格曼（Evan Seigerman）说："美学业务本季度的再次疲软可能会引起一些人的关注......包括肉毒杆菌毒素和填充剂在内的各种产品都面临着持续的不利因素。
** 公司报告 (link) 第三季度每股收益 1.86 美元，分析师平均预期每股收益 1.77 美元 - LSEG 数据
** 公司季度收入157.8亿美元，高于分析师平均预期的155.9亿美元
** ABBV将年度利润预期从之前的10.38-10.58美元/时上调至10.61-10.65美元/时
** 包括本交易日在内，ABBV股价年累计上涨约28%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.